Company intelligence / Profile preview

Edvince

Lund, Sweden

Ownership: Private
Development stage: Other

Overview

Edvince is a Swedish biotechnology company focused on developing novel therapies for cerebrovascular diseases, specifically targeting subarachnoid hemorrhage (SAH). The company's lead candidate, EDV2209, is a MEK1/2 inhibitor designed to prevent delayed cerebral ischemia (DCI), a common and devastating complication following a brain bleed. By inhibiting the MEK/ERK pathway, Edvince aims to reduce the vascular inflammation and constriction that leads to secondary brain injury. The company was founded based on the research of Professor Lars Edvinsson, a world-renowned expert in cerebral circulation. Edvince is headquartered in Lund, Sweden, within the Medicon Village innovation hub.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Edvince.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edvince.

Explore the full profile